LQDA, US53635D2027

Liquidia stock: YUTREPIA sales reach USD 222.7 million

Published on 11/10/2026 at 22:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Liquidia stock reported strong YUTREPIA demand in the third quarter. A global settlement removes major litigation uncertainty but carries significant payment obligations.

Results reshape Liquidia's outlook

YUTREPIA sales grew strongly in the third quarter, while October shipments reached their highest monthly level since launch.
A global settlement resolved Liquidia's litigation with United Therapeutics but created a large one-time charge and substantial payment obligations.
Fast Track status and new clinical studies expand the company's pipeline beyond its current pulmonary arterial hypertension business.

LQDA, US53635D2027, Illustration mit AI erstellt.

Liquidia said on Tuesday, November 10, 2026, that YUTREPIA sales and clinical development advanced in the third quarter, while a global settlement with United Therapeutics reshaped the company's financial profile. The Liquidia release covers the period ended September 30, 2026.

Liquidia stock traded at 46.24 euros on Lang & Schwarz at 22:42 CET on Tuesday, November 10, 2026.

Commercial momentum meets settlement charge

Net product sales of YUTREPIA, an inhaled treprostinil treatment, reached USD 222.7 million in the quarter, up 31 percent from the second quarter. Paid patient demand contributed USD 212.2 million, and Liquidia said October shipments reached their highest monthly level since the product launched.

Total revenue was USD 225.3 million, including USD 2.6 million of service revenue. The company recorded a GAAP net loss of USD 236.3 million, or USD 2.64 per diluted share, after recognizing a USD 389.7 million litigation settlement charge. Excluding that charge, non-GAAP adjusted EBITDA rose to USD 140.5 million, marking a fifth consecutive quarterly increase.

Litigation ends, cash obligations remain

The settlement entered on October 13 resolved six pending lawsuits with United Therapeutics. YUTREPIA remains available to patients, but Liquidia agreed to remove the PH-ILD indication from the product label and stop promoting YUTREPIA for that use. Net settlement payments of USD 380.7 million are scheduled across 2026 and 2027.

Cash and cash equivalents stood at USD 396.1 million on September 30 before settlement payments. For investors, the central question is whether continuing YUTREPIA growth can support the settlement schedule while the company funds its development programs.

Pipeline adds longer-term catalysts

Liquidia initiated RE-WARM, a Phase 2 study of YUTREPIA in adults with systemic sclerosis and symptomatic Raynaud's phenomenon, after the FDA granted Fast Track designation. The company also continued studies of L606, an investigational extended-release treprostinil formulation, in pulmonary hypertension.

The broader US market remains an important backdrop for Liquidia stock investors. Follow the S&P 500 for the wider market environment.

More updates are collected on More news and analyses on Liquidia stock.